The novel human coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has caused a pandemic. There are currently several marketed vaccines and many in clinical trials targeting SARS-CoV-2. Another strategy is to repurpose approved drugs to decrease the burden of the COVID-19 (official name for the coronavirus disease) pandemic. as the FDA (U.S. Food and Drug Administration) approved antiviral drugs and anti-inflammatory drugs to arrest the cytokine storm, inducing the production of pro-inflammatory cytokines. Another view to solve these unprecedented challenges is to analyze the diverse nanotechnological approaches which are able to improve the COVID-19 pandemic. In this original minireview, as promising candidates we analyze the opportunity to develop biocompatible dendrimers as drugs themselves or as nanocarriers against COVID-19 disease. From the standpoint of COVID-19, we suggest developing dendrimers as shields against COVID-19 infection based on their capacity to be incorporated in several environments outside the patients and as important means to stop transmission of SARS-CoV-2.

中文翻译：

---

功能化树枝状大分子平台作为针对 SARS-CoV-2 的新前沿武器库：一个机会

新型人类冠状病毒 SARS-CoV-2（严重急性呼吸综合征冠状病毒 2）已引起大流行。目前有多种针对 SARS-CoV-2 的上市疫苗，许多疫苗正处于临床试验阶段。另一种策略是重新调整已批准药物的用途，以减轻 COVID-19（冠状病毒病的官方名称）大流行的负担。随着FDA（美国食品和药物管理局）批准抗病毒药物和抗炎药物来阻止细胞因子风暴，诱导促炎细胞因子的产生。解决这些前所未有的挑战的另一种观点是分析能够改善 COVID-19 大流行的各种纳米技术方法。在这篇最初的小型评论中，作为有前途的候选者，我们分析了开发生物相容性树枝状大分子作为药物本身或作为对抗 COVID-19 疾病的纳米载体的机会。从 COVID-19 的角度来看，我们建议开发树枝状大分子作为抵御 COVID-19 感染的屏障，因为它们能够融入患者体外的多种环境中，并且可以作为阻止 SARS-CoV-2 传播的重要手段。